Skip to main content

Advertisement

Table 2 Baseline characteristics of 1227 patients who underwent resection for hepatocellular carcinoma with regular follow-up stratified by risk of recurrence and follow-up interval

From: Long- versus short-interval follow-up after resection of hepatocellular carcinoma: a retrospective cohort study

Characteristics Low-risk patients High-risk patients
Long interval Short interval P Long interval Short interval P
(n = 390) (n = 475) (%) (n = 149) (%) (n = 213) (%)
Gender    0.926    0.001
 Male 344 (88.2) 418 (88)   123 (82.6) 199 (93.4)  
 Female 46 (11.8) 57 (12.0)   26 (17.4) 14 (6.6)  
Age (years) 52 (14) 50 (19) 0.072 51 (17) 49 (17) 0.292
Tumor number    0.273    0.891
 Solitary 359 (92.1) 427 (89.9)   92 (61.7) 130 (61)  
 Multiple 31 (7.9) 48 (10.1)   57 (38.3) 83 (39)  
Tumor size (cm)    0.458    0.674
 > 5 60 (15.4) 82 (17.3)   109 (73.2) 160 (75.1)  
 ≤ 5 330 (84.6) 393 (82.7)   40 (26.8) 53 (24.9)  
 Tumor size (cm) 3.5 (2.0) 3.5 (2.3) 0.288 8 (5.0) 8 (4.8) 0.916
Tumor location    0.054    0.287
 Central 96 (24.6) 145 (30.5)   16 (10.7) 16 (7.5)  
 Subcapsular 294 (75.4) 330 (69.5)   133 (89.3) 197 (92.5)  
Tumor differentiation    0.393    0.761
 Poor 45 (11.5) 64 (13.5)   20 (13.4) 31 (14.6)  
 Moderate and well 345 (88.5) 411 (86.5)   129 (86.6) 182 (85.4)  
Tumor MVI    0.627    0.126
 Yes 27 (6.9) 29 (6.1)   95 (63.8) 152 (71.4)  
 No 363 (93.1) 446 (93.9)   54 (36.2) 61 (28.6)  
BCLC stage    0.604    0.238
 0/A 380 (97.4) 460 (96.8)   110 (73.8) 145 (68.1)  
 B 10 (2.6) 15 (3.2)   39 (26.2) 68 (31.9)  
Etiology    0.901    0.694
 Non-hepatitis 37 (9.5) 47 (9.9)   18 (12.1) 22 (10.3)  
 HBV 347 (89) 420 (88.4)   129 (86.6) 189 (88.7)  
 HCV 6 (1.5) 8 (1.7)   2 (1.3) 2 (0.9)  
WBC (109/L) 5.8 (1.9) 5.9 (2.3) 0.189 6.0 (2) 6.5 (2.8) 0.014
RBC (109/L) 4.73 (0.7) 4.8 (0.7) 0.123 4.75 (0.7) 4.81 (0.7) 0.460
 Hemoglobin (g/L) 147 (16.4) 146.7 (18) 0.922 144 (22) 145.9 (20.9) 0.392
PLT (109/L) 161.3 (79.3) 162 (72) 0.526 192 (88) 189 (77) 0.643
ALT (U/L) 36.9 (27.2) 36.1 (23.7) 0.857 37 (26.7) 39.8 (29.6) 0.196
AST (U/L) 31.2 (16.8) 31.5 (14.8) 0.882 39.4 (25.4) 40.7 (25.2) 0.774
ALB (g/L) 42.8 (4.6) 43.1 (4.5) 0.083 42.2 (4.7) 43 (4.4) 0.074
TBIL (μmol/L) 12.9 (5.9) 13.4 (6.5) 0.129 12.2 (6.2) 12.7 (5.8) 0.502
PT (s) 11.7 (1.3) 11.6 (1.2) 0.590 11.6 (1.2) 11.6 (1.1) 0.615
ALBI grade    0.720    0.432
 I 335 (85.9) 412 (86.7)   116 (77.9) 173 (81.2)  
 II 55 (14.1) 63 (13.3)   33 (22.1) 40 (18.8)  
AFP (ng/mL)    0.289    0.905
 > 200 111 (28.5) 151 (31.8)   66 (44.3) 93 (43.7)  
 ≤ 200 279 (71.5) 324 (68.2)   83 (55.7) 120 (56.3)  
Cirrhosis    0.957    0.296
 Yes 288 (73.8) 350 (73.7)   95 (63.8) 147 (69)  
 No 102 (26.2) 125 (26.3)   54 (36.2) 66 (31)  
Resection margin (cm) 1 (1.5) 1 (1.15) 0.526 1 (1.5) 1 (1.5) 0.894
Operative blood loss (ml)    0.691    0.173
 > 400 45 (11.5) 59 (12.4)   52 (34.9) 60 (28.2)  
 ≤ 400 345 (88.5) 416 (87.6)   97 (65.1) 153 (71.8)  
  1. Values are presented as the median (interquartile range) or n (%)
  2. MVI microvascular invasion, BCLC stage Barcelona clinic liver cancer stage, HBV hepatitis B virus, HCV hepatitis C virus, WBC white blood cell, RBC red blood cell, PLT platelet, ALT alanine aminotransferase, AST aspartate aminotransferase, ALB albumin, TBIL total bilirubin, PT prothrombin time, ALBI albumin-bilirubin, AFP alpha-fetoprotein